# Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

> **NCT01763385** · PHASE2 · UNKNOWN · sponsor: **Wu Jieping Medical Foundation** · enrollment: 210 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Erlotinib
- **RADIATION:** concurrent brain radiotherapy
- **RADIATION:** secondary brain radiotherapy

## Key facts

- **NCT ID:** NCT01763385
- **Lead sponsor:** Wu Jieping Medical Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2014-12-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763385, "Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01763385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*